J. Keldenich

发表

Multilamellar Liposomes and Solid-Supported Lipid Membranes (TRANSIL): Screening of Lipid-Water Partitioning Toward a High-Throughput Scale

Jörg Keldenich, A. Loidl-Stahlhofen, T. Hartmann, 2001, Pharmaceutical Research.

COSMOmic: a mechanistic approach to the calculation of membrane-water partition coefficients and internal distributions within membranes and micelles.

Andreas Klamt, Jörg Keldenich, Uwe Huniar, 2008, The journal of physical chemistry. B.

CypScore: Quantitative Prediction of Reactivity toward Cytochromes P450 Based on Semiempirical Molecular Orbital Theory

Timothy Clark, Matthias Hennemann, Alexander Hillisch, 2009, ChemMedChem.

Solid‐Supported Biomolecules on Modified Silica Surfaces—A Tool for Fast Physicochemical Characterization and High‐Throughput Screening

W. Schmitt, A. Loidl-Stahlhofen, T. Hartmann, 2001 .

A physiological model for the estimation of the fraction dose absorbed in humans.

Walter Schmitt, Stefan Willmann, Jörg Keldenich, 2004, Journal of medicinal chemistry.

Prediction of human clearance (CL) and volume of distribution (VD).

J. Keldenich, 2004, Drug discovery today. Technologies.

A Physiologic Model for Simulating Gastrointestinal Flow and Drug Absorption in Rats

W. Schmitt, J. Dressman, J. Keldenich, 2003, Pharmaceutical Research.

Mimicking Hypoxia to Treat Anemia: HIF-Stabilizer BAY 85-3934 (Molidustat) Stimulates Erythropoietin Production without Hypertensive Effects

J. Keldenich, I. Flamme, F. Oehme, 2014, PloS one.

Functional characterization and comparison of the outer blood-retina barrier and the blood-brain barrier.

B. Schlosshauer, D. Stoll, J. Keldenich, 2005, Investigative ophthalmology & visual science.

Effects of Different Pulmonary Vasodilators on Arterial Saturation in a Model of Pulmonary Hypertension

J. Stasch, M. Bechem, J. Keldenich, 2013, PloS one.

New helicase-primase inhibitors as drug candidates for the treatment of herpes simplex disease

J. Keldenich, U. Bach, K. Henninger, 2002, Nature Medicine.

Biphenyls as potent vitronectin receptor antagonists. Part 3: Squaric acid amides.

J. Keldenich, Andrea Vaupel, K. Lustig, 2007, Bioorganic & medicinal chemistry letters.

Discovery of Molidustat (BAY 85‐3934): A Small‐Molecule Oral HIF‐Prolyl Hydroxylase (HIF‐PH) Inhibitor for the Treatment of Renal Anemia

J. Keldenich, Hans-Christian Militzer, I. Flamme, 2018, ChemMedChem.

Derives du type 9-dialkylaminopurinone

J. Keldenich, K. Schlemmer, E. Bischoff, 1999 .

Stern potential near gold and chromium surfaces in contact with aqueous and alcoholic ammonium salt solutions

J. Keldenich, G. Peschel, 1991 .

Volume to dissolve applied dose (VDAD) and apparent dissolution rate (ADR): tools to predict in vivo bioavailability from orally applied drug suspensions.

Jörg Keldenich, Andreas H Göller, Uwe Muenster, 2011, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

Mode of action of the leukotriene synthesis (FLAP) inhibitor BAY X 1005: Implications for biological regulation of 5-lipoxygenase

A. Hatzelmann, J. Keldenich, U. Pleiss, 1994, Agents and Actions.

In Silico ADMET Traffic Lights as a Tool for the Prioritization of HTS Hits

Alexander Hillisch, Heinrich Meier, Mario Lobell, 2006, ChemMedChem.

In Silico Prediction of Buffer Solubility Based on Quantum-Mechanical and HQSAR- and Topology-Based Descriptors

Timothy Clark, Andreas H. Göller, Matthias Hennemann, 2006, J. Chem. Inf. Model..

Leukotriene Synthesis Inhibitors of the Quinoline Type: Parameters for the Optimization of Efficacy

B. Beckermann, J. Goossens, A. Hatzelmann, 1995, European Journal of Medicinal Chemistry.